James Fulforth

James Fulforth

Auto-generated profile, based on publicly available information

James Fulforth

Edinburgh IBD Unit, NHS Lothian, Western General Hospital, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Gut
Verified
Journal Article
Open access
PDF file
GJGareth-Rhys Jones
Gareth-Rhys Jones
MLMathew Lyons
Mathew Lyons
NPNikolas Plevris
Nikolas Plevris
PJPhilip W Jenkinson
Philip W Jenkinson
CBCathy Bisset
Cathy Bisset
CLCharlie W Lees
Charlie W Lees
Objective IBD prevalence is estimated to be rising, but no detailed, recent UK data are available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to establish the current, and project future, prevalence in Lothian, Scotland. Design We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997–2018), IBD pathology coding (1990–2018), primary and secondary care prescribing data (2009–2018) and a paediatric registry, (1997–2018) to identify ‘possible’ IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per Lennard-Jones/Porto criteria. Autoregressive integrated moving average (ARIMA) regression was applied to forecast prevalence to 01/08/2028. Results In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn’s disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture–recapture methods identified an additional 427 ‘missed’ cases (95% CI 383 to 477) resulting in a ‘true’ prevalence of 832/100 000 (95% CI 827 to 837). Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p80 years of age. Conclusions We report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide.

6 September 2015 in Liver International
Verified
Journal Article
Closed access
PDF file
NDNik S. Ding
Nik S. Ding
TNTin Nguyen
Tin Nguyen
DIDavid M. Iser
David M. Iser
THThai Hong
Thai Hong
EFEmma Flanagan
Emma Flanagan
ATAlexander J. Thompson
Alexander J. Thompson

1 September 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
NPNikolas Plevris
Nikolas Plevris
JFJames Fulforth
James Fulforth
MLMathew Lyons
Mathew Lyons
SSSpyros I. Siakavellas
Spyros I. Siakavellas
PJPhilip W. Jenkinson
Philip W. Jenkinson
CLCharlie W. Lees
Charlie W. Lees

17 March 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
MLMathew Lyons
Mathew Lyons
LDLauranne A. A. P. Derikx
Lauranne A. A. P. Derikx
JFJames Fulforth
James Fulforth
SMSophie McCall
Sophie McCall
NPNikolas Plevris
Nikolas Plevris
GJGareth‐Rhys Jones
Gareth‐Rhys Jones
Summary: Objective: It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has translated into the causes and rates of hospitalisation, particularly in an era of increased biologic prescribing. We aimed to analyse these trends in a population‐based IBD cohort over the last 10 years.Design: The Lothian IBD registry is a complete, validated, prevalent database of IBD patients in NHS Lothian, Scotland. ICD‐10 coding of hospital discharge letters from all IBD patient admissions to secondary care between 1 January 2010 and 31 December 2019 was interrogated for admission cause, with linkage to local/national data sets on death and prescribed drugs.Results: Fifty‐seven per cent (4673/8211) of all IBD patients were admitted to secondary care for >24 h between 1 January 2010 and 31 December 2019. In patients 60 years (19% of admissions). Three per cent (243/8211) of IBD patients accounted for 50% of the total IBD bed‐days over the study period.Age‐standardised IBD admission rates fell from 39.4 to 25.5 admissions per 100,000 population between 2010 and 2019, an average annual percentage reduction of 3% (95% CI −4.5% to −2.1%, p < 0.0001). Non‐IBD admission rates were unchanged overall (145–137 per 100,000 population) and specifically for serious (hospitalisation) and severe (ITU admission or death) infection over the same period.Conclusion: Despite compounding prevalence and increased biologic use, IBD admission rates are falling. The cause of admission varies with age, with infection the predominant cause in older patients.

27 March 2023 in Internal Medicine Journal
Verified
Journal Article
Closed access
SSSamir Seleq
Samir Seleq
FWFrank Weilert
Frank Weilert
JFJames Fulforth
James Fulforth

11 July 2025 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
RPRoss Porter
Ross Porter
MSMichael Song
Michael Song
SGSarah-Louise Gillespie
Sarah-Louise Gillespie
GBGrace Ball
Grace Ball
NPNikolas Plevris
Nikolas Plevris
SDShahida Din
Shahida Din
Objective Inflammatory bowel disease (IBD) colorectal cancer (CRC) surveillance aims to reduce cancer-associated mortality. We report outcomes of IBD-CRC colonoscopy surveillance, highlight missed surveillance opportunities and identify factors associated with dysplasia and CRC over a 10-year period at our centre. Methods Endoscopy software was interrogated for ‘IBD surveillance’ procedures from April 2008 to December 2018, to capture the surveillance cohort. Local databases were searched for all IBD-CRC cases outside surveillance. Follow-up was until August 2024. Results 1892 IBD surveillance colonoscopies from 1262 patients identified 144 cases of dysplasia (105/1892 sporadic; 16/1892 IBD-associated; 7/1892 indefinite for IBD-dysplasia; 16/1892 unspecified dysplasia aetiology). IBD-CRC was rare at 0.75 cases per 1000 patient years. Of the 21 IBD-CRC cases identified in this cohort, 8 were appropriately surveillance-detected within their correct surveillance interval. Of the remaining 13 cancers detected by other means, 7 were overdue surveillance. Factors associated with developing cancer were prior dysplasia (OR 10.84, 95% CI 4.46 to 26.36) (p<0.001), inflammatory pseudopolyps (OR 4.32, 95% CI 1.78 to 10.44) (p=0.001) and IBD disease duration (OR 1.04, 95% CI 1.002 to 1.08) (p=0.036). The 3-year postcolonoscopy CRC rate was 14.3%. Outside this surveillance cohort, 43 additional IBD-CRCs were identified; patients were more likely to have Crohn’s disease (p=0.040) and shorter disease duration (p<0.001). Cancer stage at presentation (p=0.609) and overall survival (p=0.679) was not different between the surveillance and non-surveillance cohorts. Conclusions In this real-world cohort, active surveillance did not improve cancer survival compared with patients whose cancer was detected by other means. A modern approach is needed to maximise the potential benefits of surveillance.